Skip to main content
RENHE PHARMACY CO.,LTD logo

RENHE PHARMACY CO.,LTD — Investor Relations & Filings

Ticker · 000650 ISIN · CNE000000NF8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,739 across all filing types
Latest filing 2025-12-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000650

About RENHE PHARMACY CO.,LTD

https://www.renheyaoye.com

Renhe Pharmacy Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products and health-related commodities. The company maintains a diverse portfolio encompassing over-the-counter (OTC) medications, traditional Chinese medicines (TCM), health supplements, and personal care items. Its core product lines address various therapeutic areas, including respiratory health, digestive disorders, gynecology, and pediatrics. Renhe is recognized for its established brand equity, operating well-known labels such as Renhe, Youka, and Fuyan. The company integrates modern pharmaceutical technology with traditional medicinal practices to produce high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and an extensive marketing network, focusing on providing accessible healthcare products to a broad consumer base.

Recent filings

Filing Released Lang Actions
仁和药业2025年第二次临时股东会法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and voting results of the 2025 second extraordinary general meeting (临时股东会) of Renhe Pharmaceutical Co., Ltd. It details the legality and validity of the meeting's call, attendance, voting procedures, and results. The document is not a report of financial results, audit, or management discussion, nor is it a simple announcement or certification. It is a legal opinion specifically related to a shareholders' meeting, which is a specialized type of regulatory filing but does not fit into categories like AGM Information (which are presentations/materials shared during the AGM) or Declaration of Voting Results (which would be the official voting results announcement). Instead, it is a legal opinion letter accompanying or related to the shareholders' meeting. Given the absence of a more specific category for legal opinions on shareholder meetings, and since it is a legal opinion report, the best fit is Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not neatly fit elsewhere. The document length is short (2715 characters), and it is not an announcement of a report but the report itself (legal opinion). Therefore, classification as RNS is appropriate with high confidence.
2025-12-26 Chinese
国泰海通证券股份有限公司关于仁和药业股份有限公司调整部分募投项目投资规模并结项、终止部分项目并将相关募集资金永久补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (Guotai Huatong Securities Co., Ltd.) regarding the adjustment of investment scale, termination of certain fundraising projects, and permanent supplementation of working capital for Renhe Pharmaceutical Co., Ltd. It references regulatory approvals, fundraising details, project investment adjustments, board and shareholder meeting approvals, and compliance with relevant securities regulations. The content focuses on the use and adjustment of funds raised through a non-public stock issuance, with detailed financial figures and project status updates. This type of document is a formal audit or verification report related to fundraising and capital use, not a full annual or interim financial report, nor a simple announcement. It fits the category of an Audit Report / Information (AR) as it involves verification and audit opinions on fundraising and project investment adjustments, consistent with the description of standalone audit reports and applied accounting principles related to fundraising projects. FY 2025
2025-12-09 Chinese
仁和药业股份有限公司关于调整部分募投项目投资规模并结项、终止部分项目并将相关募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Renhe Pharmaceutical Co., Ltd. regarding adjustments to the investment scale of certain fundraising projects, termination of some projects, and the permanent supplementation of related raised funds into working capital. It includes detailed information about the fundraising, project investment adjustments, reasons for termination, and the use of remaining funds. The document references approvals by the board and shareholders, and includes financial figures related to fundraising and project investments. It is a regulatory announcement about the use and adjustment of capital raised through a non-public stock issuance, rather than a full financial report or earnings release. The document is not a full annual or interim report, audit report, or earnings release, but rather a capital/financing update about the use of raised funds and project investment changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5419 characters) and content support this classification with high confidence.
2025-12-09 Chinese
仁和药业股份有限公司第十届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth meeting of the tenth board of directors of Renhe Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on specific proposals. The content focuses on board decisions, such as adjustments to investment projects and scheduling a shareholders' meeting. There is no detailed financial data, audit information, or full report content. The document is not a full annual or interim report, nor is it a call transcript or earnings release. It is clearly a Board/Management Information announcement regarding board meeting resolutions and decisions. The document length is short (894 characters), and it is a direct announcement of board meeting outcomes, fitting the Board/Management Information (MANG) category.
2025-12-09 Chinese
仁和药业股份有限公司关于召开2025年第二次临时股东会的通知_
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 second extraordinary general meeting of shareholders (临时股东会) for Renhe Pharmaceutical Co., Ltd. It includes details about the meeting time, location, voting procedures, registration, and agenda items. It does not contain financial statements or results but is an announcement informing shareholders about the meeting and how to participate. The document length is 3572 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document is best classified as a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-12-09 Chinese
关于控股股东减持股份预披露的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a planned reduction in shareholding by the controlling shareholder of the company. It details the shareholder's current holdings, the number and percentage of shares intended to be sold, the reasons for the sale, the planned timeframe, and compliance with relevant regulations. There are no financial statements, earnings data, or management discussion of financial results. The document is a formal disclosure of a shareholding change plan, which fits the category of Major Shareholding Notification (MRQ). The document length is short (1917 characters), and it is not an announcement of a report publication but a substantive notification about shareholding changes.
2025-11-13 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.